- $68.12m
- $43.65m
- $0.92m
Brief: Cyclo Therapeutics Provides Business Update And Reports First Quarter 2023 Financial Results
Brief: Rafael Holdings Reports Q2 Fiscal 2023 Financial Results
Brief: Protara Therapeutics Announces Appointment Of Patrick Fabbio As CFO
Brief: Rafael Holdings Inc - Effective January 27, 2023, Patrick Fabbio, Current Chief Financial Officer Of Company, Would Be Departing Company
Brief: Rafael Holdings Reports Q1 Loss Per Share Of $0.22
Brief: Rafael Holdings To Focus On Strategic Business Development Initiatives, Curtail Early Stage Development Activities
Brief: Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results
Brief: Cornerstone Pharmaceuticals Initiates Phase 1 Trial Of CPI-613 In Combination With Chemoradiation For Treatment Of Advanced Pancreatic Cancer
Brief: Rafael Holdings Sells Its Building Located At 520 Broad Street In Newark, New Jersey And Associated 800-Car Public Garage
NYSE RESUMED RAFAEL HLDN CL B
NYSE ORDER IMBALANCE 81097.0 SHARES ON SELL SIDE
Brief: Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results
NYSE ORDER IMBALANCE 81479.0 SHARES ON BUY SIDE
Brief: Rafael Holdings Reports Q2 Fiscal 2022 Financial Results
Brief: Rafael Holdings Management Concluded That, For Quarter Ended, Oct 31, 2021, Existed Material Weaknesses In Internal Control Over Financial Reporting
Brief: Rafael Holdings Inc - Selling Stockholders May Sell, Resell Or Otherwise Dispose Of Up To 2.8 Million Shares Of Co's Class B Common Stock
Brief: Rafael Holdings Inc - On Feb 2, Co Delivered Letter To Rafael Pharmaceuticals Pursuant To Which Co Terminated Merger Agreement, Effective Immediately
Brief: Rafael Holdings- William “Bill” Conkling To Assume The Role Of Chief Executive Officer As Of February 1, 2022
Brief: Rafael Pharmaceuticals Announces Ongoing Successful Enrollment And Opening Of Additional Sites For Phase 2 Clinical Trial Of Cpi-613®